Low Dose of Hydroxychloroquine Reduces Fatality of Critically Ill Patients With COVID-19

{ 'indexed': {'date-parts': [[2024, 3, 29]], 'date-time': '2024-03-29T11:53:24Z', 'timestamp': 1711713204561}, 'reference-count': 19, 'publisher': 'Springer Science and Business Media LLC', 'issue': '10', 'license': [ { 'start': { 'date-parts': [[2020, 5, 15]], 'date-time': '2020-05-15T00:00:00Z', 'timestamp': 1589500800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}, { 'start': { 'date-parts': [[2020, 5, 15]], 'date-time': '2020-05-15T00:00:00Z', 'timestamp': 1589500800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020, 10]]}, 'DOI': '10.1007/s11427-020-1732-2', 'type': 'journal-article', 'created': {'date-parts': [[2020, 5, 16]], 'date-time': '2020-05-16T04:02:53Z', 'timestamp': 1589601773000}, 'page': '1515-1521', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 87, 'title': 'Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19', 'prefix': '10.1007', 'volume': '63', 'author': [ {'given': 'Bo', 'family': 'Yu', 'sequence': 'first', 'affiliation': []}, {'given': 'Chenze', 'family': 'Li', 'sequence': 'additional', 'affiliation': []}, {'given': 'Peng', 'family': 'Chen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ning', 'family': 'Zhou', 'sequence': 'additional', 'affiliation': []}, {'given': 'Luyun', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jia', 'family': 'Li', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hualiang', 'family': 'Jiang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dao-Wen', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2020, 5, 15]]}, 'reference': [ { 'key': '1732_CR1', 'doi-asserted-by': 'publisher', 'first-page': '1608', 'DOI': '10.1093/jac/dkv018', 'volume': '70', 'author': 'MAA Al-Bari', 'year': '2015', 'unstructured': 'Al-Bari, M.A.A. (2015). Chloroquine analogues in drug discovery: new ' 'directions of uses, mechanisms of actions and toxic manifestations from ' 'malaria to multifarious diseases. J Antimicrob Chemother 70, 1608–1621.', 'journal-title': 'J Antimicrob Chemother'}, { 'key': '1732_CR2', 'doi-asserted-by': 'publisher', 'DOI': '10.21203/rs.3.rs-19346/v1', 'volume-title': 'Immunol Pathol', 'author': 'X Bian', 'year': '2020', 'unstructured': 'Bian, X., Shi, Z., Chen, R., Cai, J., Wang, C., Xie, J., Zhao, L., Fei, ' 'X., Zhang, H., Tan, Y., et al. (2020). Aveolar macrophage activation and ' 'cytokine storm in the pathogenesis of severe COVID-19. Immunol Pathol, ' 'https://doi.org/10.21203/rs.3.rs-19346/v1.'}, { 'key': '1732_CR3', 'doi-asserted-by': 'crossref', 'unstructured': 'Gautret, P., Lagier, J.C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe, ' 'M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V.E., et al. ' '(2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: ' 'results of an open-label non-randomized clinical trial. Int J Antimicrob ' 'Ag 20, 105949.', 'DOI': '10.1016/j.ijantimicag.2020.105949'}, { 'key': '1732_CR4', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2012410', 'volume-title': 'N Engl J Med', 'author': 'J Geleris', 'year': '2020', 'unstructured': 'Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., ' 'Labella, A., Manson, D., Kubin, C., Barr, R.G., et al. (2020). ' 'Observational Study of Hydroxychloroquine in Hospitalized Patients with ' 'Covid-19. N Engl J Med https://doi.org/10.1056/NEJMoa2012410.'}, { 'key': '1732_CR5', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2007016', 'volume-title': 'N Engl J Med', 'author': 'J Grein', 'year': '2020', 'unstructured': 'Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., ' 'Feldt, T., Green, G., Green, M.L., Lescure, F.X., et al. (2020). ' 'Compassionate use of remdesivir for patients with severe Covid-19. N ' 'Engl J Med https://doi.org/10.1056/NEJMoa2007016.'}, { 'key': '1732_CR6', 'doi-asserted-by': 'publisher', 'first-page': '1708', 'DOI': '10.1056/NEJMoa2002032', 'volume': '382', 'author': 'WJ Guan', 'year': '2020', 'unstructured': 'Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., Liu, L., ' 'Shan, H., Lei, C.L., Hui, D.S.C., et al. (2020). Clinical ' 'characteristics of coronavirus disease 2019 in China. N Engl J Med 382, ' '1708–1720.', 'journal-title': 'N Engl J Med'}, { 'key': '1732_CR7', 'doi-asserted-by': 'crossref', 'unstructured': 'He, Y., Xu, Y., Zhang, C., Gao, X., Dykema, K.J., Martin, K.R., Ke, J., ' 'Hudson, E.A., Khoo, S.K., Resau, J.H., et al. (2011). Identification of ' 'a lysosomal pathway that modulates glucocorticoid signaling and the ' 'inflammatory response. Sci Signal 4, ra44.', 'DOI': '10.1126/scisignal.2001450'}, { 'key': '1732_CR8', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.25801.', 'volume-title': 'J Med Virol', 'author': 'P Luo', 'year': '2020', 'unstructured': 'Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., and Li, J. (2020). ' 'Tocilizumab treatment in COVID-19: a single center experience. J Med ' 'Virol https://doi.org/10.1002/jmv.25801.'}, { 'key': '1732_CR9', 'doi-asserted-by': 'publisher', 'DOI': '10.1101/2020.04.16.20065920', 'volume-title': 'MedRxiv', 'author': 'J Magagnoli', 'year': '2020', 'unstructured': 'Magagnoli, J., Narendran, S., Pereira, F., Cummings, T., Hardin, J., ' 'Sutton, S.S., and Ambati, J. (2020). Outcomes of hydroxychloroquine ' 'usage in United States veterans hospitalized with Covid-19. MedRxiv, ' 'https://doi.org/10.1101/2020.04.16.20065920.'}, { 'key': '1732_CR10', 'doi-asserted-by': 'publisher', 'DOI': '10.1101/2020.04.10.20060699', 'volume-title': 'MedRxiv', 'author': 'M Mahevas', 'year': '2020', 'unstructured': 'Mahevas, M., Thi Tran, V., Roumier, M., Chabrol, A., Paule, R., ' 'Guillaud, C., Gallien, S., Lepeule, R., Szwebel, T.A., Lescure, X., et ' 'al. (2020). No evidence of clinical efficacy of hydroxychloroquine in ' 'patients hospitalized for COVID-19 infection with oxygen requirement: ' 'results of a study using routinely collected data to emulate a target ' 'trial. MedRxiv, https://doi.org/10.1101/2020.04.10.20060699.'}, { 'key': '1732_CR11', 'doi-asserted-by': 'publisher', 'first-page': '501', 'DOI': '10.1016/0041-008X(67)90089-0', 'volume': '10', 'author': 'EW McChesney', 'year': '1967', 'unstructured': 'McChesney, E.W., Banks Jr., W.F., and Fabian, R.J. (1967). Tissue ' 'distribution of chloroquine, hydroxychloroquine, and desethylchloroquine ' 'in the rat. Toxicol Appl Pharmacol 10, 501–513.', 'journal-title': 'Toxicol Appl Pharmacol'}, { 'key': '1732_CR12', 'volume-title': 'Chinese management guideline for COVID-19 (version 5.0)', 'author': 'National Health Commission of China.', 'year': '2020', 'unstructured': 'National Health Commission of China. (2020). Chinese management ' 'guideline for COVID-19 (version 5.0). ' 'http://wwwnhcgovcn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml.'}, { 'key': '1732_CR13', 'doi-asserted-by': 'publisher', 'first-page': '653', 'DOI': '10.1007/s40261-018-0656-y', 'volume': '38', 'author': 'D Plantone', 'year': '2018', 'unstructured': 'Plantone, D., and Koudriavtseva, T. (2018). Current and future use of ' 'chloroquine and hydroxychloroquine in infectious, immune, neoplastic, ' 'and neurological diseases: a mini-review. Clin Drug Invest 38, 653–671.', 'journal-title': 'Clin Drug Invest'}, { 'key': '1732_CR14', 'doi-asserted-by': 'publisher', 'first-page': '231', 'DOI': '10.1007/s10787-015-0239-y', 'volume': '23', 'author': 'KD Rainsford', 'year': '2015', 'unstructured': 'Rainsford, K.D., Parke, A.L., Clifford-Rashotte, M., and Kean, W.F. ' '(2015). Therapy and pharmacological properties of hydroxychloroquine and ' 'chloroquine in treatment of systemic lupus erythematosus, rheumatoid ' 'arthritis and related diseases. Inflammopharmacology 23, 231–269.', 'journal-title': 'Inflammopharmacology'}, { 'key': '1732_CR15', 'doi-asserted-by': 'crossref', 'first-page': '337', 'DOI': '10.55563/clinexprheumatol/xcdary', 'volume': '38', 'author': 'P Sarzi-Puttini', 'year': '2020', 'unstructured': 'Sarzi-Puttini, P., Giorgi, V., Sirotti, S., Marotto, D., Ardizzone, S., ' 'Riz-zardini, G., Antinori, S., and Galli, M. (2020). COVID-19, cytokines ' 'and immunosuppression: what can we learn from severe acute respiratory ' 'syndrome? Clin Exp Rheumatol 38, 337–342.', 'journal-title': 'Clin Exp Rheumatol'}, { 'key': '1732_CR16', 'doi-asserted-by': 'publisher', 'first-page': '328', 'DOI': '10.1016/j.ejphar.2018.06.017', 'volume': '833', 'author': 'H Shiratori', 'year': '2018', 'unstructured': 'Shiratori, H., Feinweber, C., Luckhardt, S., Wallner, N., Geisslinger, ' 'G., Weigert, A., and Parnham, M.J. (2018). An in vitro test system for ' 'compounds that modulate human inflammatory macrophage polarization. Eur ' 'J Pharmacol 833, 328–338.', 'journal-title': 'Eur J Pharmacol'}, { 'key': '1732_CR17', 'doi-asserted-by': 'publisher', 'first-page': '5927', 'DOI': '10.1128/JVI.02501-05', 'volume': '80', 'author': 'EJ Snijder', 'year': '2006', 'unstructured': 'Snijder, E.J., van der Meer, Y., Zevenhoven-Dobbe, J., Onderwater, ' 'J.J.M., van der Meulen, J., Koerten, H.K., and Mommaas, A.M. (2006). ' 'Ultrastructure and origin of membrane vesicles associated with the ' 'severe acute respiratory syndrome coronavirus replication complex. JVI ' '80, 5927–5940.', 'journal-title': 'JVI'}, { 'key': '1732_CR18', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa237', 'volume-title': 'Clin Infect Dis', 'author': 'X Yao', 'year': '2020', 'unstructured': 'Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, ' 'L., Dong, E., Song, C., et al. (2020). In vitro antiviral activity and ' 'projection of optimized dosing design of hydroxychloroquine for the ' 'treatment of severe acute respiratory syndrome coronavirus 2 ' '(SARS-CoV-2). Clin Infect Dis https://doi.org/10.1093/cid/ciaa237.'}, { 'key': '1732_CR19', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhang, C., Wu, Z., Li, J.W., Zhao, H., and Wang, G.Q. (2020). The ' 'cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 ' 'receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the ' 'mortality. Int J Antimicrob Ag 29, 105954.', 'DOI': '10.1016/j.ijantimicag.2020.105954'}], 'container-title': 'Science China Life Sciences', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s11427-020-1732-2.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s11427-020-1732-2/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s11427-020-1732-2.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 10, 23]], 'date-time': '2022-10-23T21:58:48Z', 'timestamp': 1666562328000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s11427-020-1732-2'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 5, 15]]}, 'references-count': 19, 'journal-issue': {'issue': '10', 'published-print': {'date-parts': [[2020, 10]]}}, 'alternative-id': ['1732'], 'URL': 'http://dx.doi.org/10.1007/s11427-020-1732-2', 'relation': {}, 'ISSN': ['1674-7305', '1869-1889'], 'subject': [ 'General Agricultural and Biological Sciences', 'General Environmental Science', 'General Biochemistry, Genetics and Molecular Biology'], 'container-title-short': 'Sci. China Life Sci.', 'published': {'date-parts': [[2020, 5, 15]]}, 'assertion': [ { 'value': '23 April 2020', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '12 May 2020', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '15 May 2020', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '18 June 2020', 'order': 4, 'name': 'change_date', 'label': 'Change Date', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'Erratum', 'order': 5, 'name': 'change_type', 'label': 'Change Type', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '<OrderedList><ListItem><ItemNumber>1.</ItemNumber><ItemContent><Para>In the ' 'abstract, we missed a piece of information. The correct sentence should be “In ' 'this retrospective study, we included 550 critically ill COVID-19 patients who ' 'need mechanical ventilation <Emphasis Type="Bold">(63.5%) and oxygen therapy ' '(35.6%)</Emphasis> in Tongji Hospital, Wuhan, from February 1, 2020 to April 4, ' '2020.”</Para></ItemContent></ListItem><ListItem><ItemNumber>2.</ItemNumber><ItemContent><Para>We ' 'mistakenly put an approval number from Tongji Hospital ethics committee in the ' 'paper (IRBID: TJ-C20200113). The correct number should be <Emphasis ' 'Type="Bold">TJ-IRB20200229</Emphasis>.</Para></ItemContent></ListItem><ListItem><ItemNumber>3.</ItemNumber><ItemContent><Para>We ' 'mistakenly filled some data in Table 1 and the correct Table 1 (the corrected ' 'data are in boldface) should be as ' 'follows:</Para></ItemContent></ListItem></OrderedList>', 'order': 6, 'name': 'change_details', 'label': 'Change Details', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'The author(s) declare that they have no conflict of interest. No funding bodies ' 'had any role in study design, data collection and analysis, decision to ' 'publish, or preparation of the manuscript.', 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Compliance and ethics'}}, { 'value': 'This content has been made available to all.', 'name': 'free', 'label': 'Free to read'}]}